Document:

<PAGE>   1

                                  Exhibit 10.6

                        SETTLEMENT AGREEMENT AND RELEASE
                        --------------------------------

         THIS SETTLEMENT AGREEMENT is made and entered into this 29th day of
October, 1999, by and among Neuromedical Systems, Inc., a debtor and
debtor-in-possession in the Chapter 11 bankruptcy case styled as In re
Neuromedical Systems, Inc., Case No. 99-00703 (PJW) (the "Debtor"), NetMed, Inc.
("NetMed") and the Official Committee of Unsecured Creditors for the bankruptcy
estate of Neuromedical Systems, Inc. (the "Committee"), subject, only, to
approval by the United States Bankruptcy Court for the District of Delaware (the
"Court").

                                    RECITALS
                                    --------

         WHEREAS, on March 26, 1999, the Debtor filed a Voluntary Petition for
relief under Chapter 11 of Title 11 of the United States Code (the "Code"); and

         WHEREAS, on April 7, 1999, the United States Trustee's Office conducted
an organizational meeting of the Debtor's creditors and, at the conclusion of
that meeting, the Committee was appointed in accordance with Code Section 1102;
and

        WHEREAS, prior to the Petition Date, the Debtor operated as a healthcare
technology company that supplied cytology screening and anatomic pathology
diagnostic equipment and services to laboratories using its patented, FDA
approved, PAPNET Testing System. The PAPNET Testing System was developed for the
screening of PAP smears by combining computerized image acquisition with neural
network artificial intelligence to assist in the detection of abnormal cells;
and

        WHEREAS, on November 23, 1998, the Debtor and NetMed formally entered
into an Amended and Restated Agreement (the "Distribution Agreement") pursuant
to which NetMed was granted an exclusive right to sell the PAPNET Service, as
defined in the Distribution Agreement and related technology in the territory
described more fully therein; and

         WHEREAS, the Debtor, prior to the Petition Date, entered into a
purchase agreement with AutoCyte, Inc. ("AutoCyte) pursuant to which AutoCyte
agreed to purchase the Debtor's intellectual property and certain related assets
for cash and publicly traded stock (the "AutoCyte Stock"); and

        WHEREAS, on or about April 6, 1999, the Debtor filed a motion seeking,
inter alia, authorization from the Court to reject the Distribution Agreement;
and

         WHEREAS, by Order of this Court dated May 3, 1999, the Court authorized
the Debtor to reject the Distribution Agreement; and

         WHEREAS, on or about July 23, 1999, NetMed filed an unsecured proof of
claim in an unliquidated amount but in no event less than $7,163,360.00 arising
from the Debtor's rejection of the Distribution Agreement and NetMed will either
amend (or has amended) this claim by

<PAGE>   2

filing an amended proof of claim in an unliquidated amount but in no event less
than $6,880,008.00 (the "Claim"); and

         WHEREAS, subsequent to the filing of the Claim, NetMed also filed a
Motion to Estimate its Claim for Voting Purposes (the "502(c) Motion"), which is
still pending before the Court;

         WHEREAS, the Debtor, on or about October 6, 1999, filed an objection to
the Claim (the "Objection") alleging, inter alia, that the Claim was
substantially overstated; and

         WHEREAS, the Committee is still in the process of investigating the
Claim the Distribution Agreement and any related documentation thereto in order
to determine the merits of the Claim and the Debtor's Objection thereto; and

         WHEREAS, the parties, including, the Committee, in an effort to avoid
the uncertainties and costs associated with protracted litigation, desire to
resolve the Objection, the Claim and the 502(c) Motion on an amicable basis and
have agreed to enter into this Agreement for that purpose.

         NOW, THEREFORE, in consideration of the premises and the mutual
promises and covenants contained herein, subject, only, to approval by the
Court, the parties, intending to be legally bound, hereby agree as follows:

                                    AGREEMENT

         1. INCORPORATION. The Recital section set forth above is incorporated
herein as though set forth at length below by this reference.

         2. ALLOWANCE OF THE CLAIM. Upon Court approval of this Agreement,
NetMed, on account of the Claim and all other claims, as defined by Code Section
101(5), it has, had or may have against the Debtor or its estate, shall be
allowed in the within bankruptcy case for all purposes: an unsecured claim in
the aggregate amount of $1.5 million (the "NetMed Unsecured Claim") to be
treated equally with the Debtor's other allowed, general, unsecured claims.

         3. RECEIPT OF THE NETMED SHARES. In consideration for entering into
this Agreement and for reducing its Claim, as set forth above, NetMed (or its
nominee), upon Court approval of this Agreement, shall receive one hundred and
seventy-five thousand (175,000) shares of the AutoCyte Stock or the number of
shares of stock of TriPath Imaging, Inc. ("TriPath"), being the
successor-in-interest to AutoCyte, Inc. and NeoPath, Inc., for which such
AutoCyte stock was exchanged (hereinafter referred to as the "NetMed Shares").

         4. DISTRIBUTION OF THE NETMED SHARES. Upon Court approval of this
Agreement, the Debtor shall promptly provide instructions to the transfer agent
for the AutoCyte/TriPath Stock to transfer the NetMed Shares to NetMed or its
nominee with such transfer to be subject to any and all securities laws, rules
and regulations. Neither the Debtor nor the Committee make any representations
or warranties as to the "transferability" or "tradeability" of such stock, it
being

                                       2
<PAGE>   3

the expressed understanding of the parties hereto that such stock shall be
transferred to NetMed on an "AS-IS, WHERE-IS" basis. Notwithstanding anything
contained herein to the contrary, neither the Debtor nor the Committee, however,
will provide any additional restrictions on either the "transferability" or the
"tradeability" of such stock.

         5. RELEASE OF DEBTOR PARTIES. Except for the NetMed Unsecured Claim,
the right to receive the NetMed Shares and its other rights hereunder, NetMed,
upon Court approval of this Agreement and upon receipt of the NetMed Shares,
hereby releases and forever discharges the Debtor, its estate and their
respective attorneys, employees, officers, directors, predecessors, successors
and assigns, and the heirs, executors, administrators, successors or assigns of
any of the foregoing (collectively, the "Debtor Parties"), of and from any and
all pre- or post-petition claims, demands, obligations, actions, causes of
action, damages, costs, losses, debts, expenses of any nature whatsoever, known,
unknown or suspected, whether based in law, equity or otherwise, which NetMed
has, had or may have against the Debtor Parties from the beginning of the world
to the date of this Agreement, including, without limitation, claims arising
from the Debtor's rejection of the Distribution Agreement.

         6. RELEASE OF NETMED PARTIES. Upon Court approval of this Agreement,
the Debtor and its estate do hereby release and forever discharge NetMed, its
respective attorneys, employees, officers, directors, predecessors, successors
and assigns, and the heirs, executors, administrators, successors or assigns of
any of the foregoing (collectively, the "NetMed Parties"), of and from any and
all pre- or post-petition claims, demands, obligations, actions, causes of
action, damages, costs, losses, debts, expenses of any nature whatsoever, known,
unknown or suspected, whether based in law, equity or otherwise, which the
Debtor or its estate have, had or may have against the NetMed Parties from the
beginning of the world to the date of this Agreement.

         7. NETMED'S REPRESENTATIONS AND WARRANTIES. NetMed represents and
warrants to the Debtor and the Committee as follows:

            (a) that NetMed has the full power, authority and legal right to
execute, deliver and comply with this Agreement;

            (b) no consent, approval or other authorization of or by any court,
administrative agency or other governmental authority is required in connection
with NetMed's execution and delivery of or compliance with this Agreement; and

            (c) NetMed's execution and delivery of and compliance with this
Agreement will not conflict with or result in a breach of any applicable law,
judgment, order, writ, injunction, decree, rule or regulation of any court,
administrative agency or other governmental authority, or of any provision of
any agreement or other document or instrument to which NetMed is a party or by
which it may be bound.

         8. COVENANTS OF THE DEBTOR AND COMMITTEE. In consideration for the
mutual promises contained herein and the significant reduction of the Claim, the
Debtor and the Committee agree to:

                                       3
<PAGE>   4

            (a) complete their "due diligence" and analysis of the Claim, the
Distribution Agreement and any and all related documentation on or before
October 22, 1999;

            (b) move for the entry of a final, non-appealable Order of the
Court, or any other court of competent jurisdiction, approving this Agreement on
or before November 4, 1999; and

            (c) prepare, file and seek confirmation of a Plan which incorporates
the terms and conditions of this Agreement.

         9. COVENANTS OF NETMED. In consideration for the mutual promises
contained herein, the allowance of the NetMed Unsecured Claim and the
distribution of the NetMed Shares, NetMed specifically agrees:

            (a) to reasonably cooperate and assist the Debtor and the Committee
in their "due diligence" and analysis of the Claim, the Distribution Agreement
and any and all related documentation. For purposes herein, such cooperation
shall include, without limitation, making witnesses available for interviews and
making documentation available for inspection and copying purposes;

            (b) to support the Debtor's and the Committee's motion for the entry
of a final, non-appealable Order of the Court, or any other court of competent
jurisdiction, approving this Agreement;

            (c) to vote in favor of any Plan which incorporates the terms and
conditions of this Agreement;

            (d) that the Claim is warranted by existing law, is based upon
credible evidentiary support and was not filed for any improper purpose,
including, without limitation, harassment, unnecessary delay or an increase in
the cost of litigation; and

            (e) to reasonably cooperate with the Debtor and the Committee
concerning the objections to proofs of claim, among others, of PUI and CWI. For
purposes herein, this cooperation will include, without limitation, making
witnesses available for interviews, for discovery and trial purposes and for
making available to the Debtor, the Committee and their respective
professionals, for inspection and copying purposes, any and all documentation
relevant to these objections, among others.

         10. CONDITIONS. This Agreement is specifically conditioned upon the
following:

             (a) the Committee completes its analysis of the Claim, the
Distribution Agreement and any and all related documentation on or before
October 22, 1999 and is reasonably satisfied with the results of such analysis;
and

                                       4
<PAGE>   5

             (b) this Agreement is approved by a final, non-appealable Order of
the Court, or any other court of competent jurisdiction, on or before December
1, 1999.

         11. EVENTS OF DEFAULT. The occurrence of any one or more of the
following events shall constitute an event of default hereunder:

             (a) the failure by NetMed to observe and perform any of the
covenants or agreements required to be performed hereunder within ten (10) days
after written notice from either the Debtor or the Committee;

             (b) the failure by either the Debtor or the Committee to observe
and perform any of the covenants or agreements required to be performed
hereunder within ten (10) days after written notice from NetMed; and

             (c) any representation or warranty of NetMed under this Agreement
shall be untrue in any material respect.

         12. REMEDIES UPON THE OCCURRENCE OF AN EVENT OF DEFAULT. Upon the
occurrence of any event of default hereunder and, if applicable, the failure to
cure within the timeframes specified herein, this Agreement shall be terminated
and the Claim, the Objection and the 502(c) Motion shall be reinstated with the
parties being entitled to engage in discovery and being afforded sufficient time
to prepare for any and all hearings or trials related thereto.

         13. NOTICES. All notices required or desired to be given to any of the
parties hereunder shall be in writing and shall be deemed to have been
sufficiently given for all purposes when presented personally to such party or
sent via either certified mail, return receipt requested, or via overnight
delivery with a nationally recognized delivery service (e.g. Fedex or DHL) to
such party or the party's authorized agent at the addresses set forth below:

             If to the Debtor:

             Josef S. Athanas, Esquire
             Latham & Watkins
             333 South Wacker Drive
             Chicago, IL  60606-6401

             If to the Committee:

             Lawrence J. Kotler, Esquire
             Buchanan Ingersoll Professional Corporation
             Eleven Penn Center, 14th Floor
             1835 Market Street
             Philadelphia, PA  19103

                                       5
<PAGE>   6

             If to NetMed:

             Neil B. Glassman, Esquire
             The Bayard Firm
             222 Delaware Avenue, Suite 900
             Wilmington, DE  19801

         Such notice shall be deemed to be given when received if delivered
personally, one (1) day after the date if sent via overnight delivery or two (2)
days after the date mailed if sent by certified mail, return receipt requested.
Any notice of any change in such address shall also be given in the manner set
forth above. Whenever the giving of notice is required, the giving of such
notice may be waived in writing by the party entitled to receive such notice.

         14. MISCELLANEOUS.

             (a) this Agreement shall be binding upon and inure to the benefit
of the parties and their respective successors, heirs and assigns. No provision
of this Agreement shall be amended, modified, waived or terminated unless each
party consents in writing;

             (b) all recitals, representations, covenants and agreements
contained herein shall survive the execution and delivery of this Agreement;

             (c) this Agreement may be executed in any number of counterparts
and by different parties hereto in separate counterparts, each of which shall be
an original and all of which taken together shall constitute one and the same
agreement;

             (d) this Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware;

             (e) the Court shall continue to retain jurisdiction over this
matter and shall hear any and all disputes arising out of, related to or in
connection with the interpretation, enforcement or implementation of this
Agreement;

             (f) upon Court approval of this Agreement, the Order approving this
Agreement shall be docketed as a settlement of the Claim, the Objection and the
502(c) Motion; and

             (g) this Agreement constitutes the entire agreement and
understanding between the parties with respect to the subject matter hereof and
this Agreement and all other documents executed pursuant to this Agreement,
supersede all previous and contemporaneous negotiations, discussions and
agreements between the parties and no parole evidence of any prior or other
agreement shall be permitted to contradict or vary the term hereof.

                                       6
<PAGE>   7

        IN WITNESS WHEREOF, the parties hereto have executed this Agreement on
the day and year first above written.

                                 NEUROMEDICAL SYSTEMS, INC.

                                 By:
                                    --------------------------------------
                                      Title:

                                 NETMED, INC.

                                 By:
                                    --------------------------------------
                                      Title:

                                 THE OFFICIAL COMMITTEE OF UNSECURED
                                 CREDITORS FOR NEUROMEDICAL
                                 SYSTEMS, INC.

                                 By:
                                    --------------------------------------
                                      Title:

                                       7<PAGE>   1

                                  Exhibit 10.7

                        INTELLECTUAL PROPERTY DEVELOPMENT
                             AND OWNERSHIP AGREEMENT

         This Intellectual Property Development and Ownership Agreement
("Agreement") is made and entered into effective this 30th day of April, 1999,
by and among MG Generon, Inc., a Delaware corporation ("Generon"), OxyNet, Inc.,
an Ohio corporation formerly named Ceram Oxygen Technologies, Inc. ("OxyNet"),
and NetMed, Inc., an Ohio corporation ("NetMed").

                                  WITNESSETH:

         WHEREAS, OxyNet owns and/or licenses certain technology used to remove
or separate oxygen from air and other gases, including certain exclusive patent
rights and technology licensed to OxyNet by CeramPhysics, Inc. pursuant to a
certain License Agreement dated February 28, 1997, as amended by an Amendment To
License Agreement dated March 31, 1998 (as amended, the "CeramPhysics License")
(as more fully defined hereinafter, the "Technology"); and

         WHEREAS, OxyNet desires to grant certain exclusive rights to the
Technology for certain applications as more fully described in this Agreement
and Generon desires to acquire and receive such rights; and

         WHEREAS, the Parties desire to set forth in writing their respective
rights and obligations in respect of the Technology and certain other matters;

         NOW, THEREFORE, INTENDING TO BE LEGALLY BOUND HEREBY, the Parties agree
as follows:

         SECTION 1 DEFINITIONS.
                   ------------

         1.1 As used in this Agreement, the following terms shall have the
meanings set forth below:

<PAGE>   2

         "Affiliate" of a Person means a Person that directly or through one or
more intermediaries, controls, is controlled by or is under common control with
such first Person, where "control" means the power to direct the management or
policies of such Person.

         "Agreement" means this Intellectual Property Development and Ownership
Agreement by and among Generon, OxyNet and NetMed.

         "Ambient Air" means a gas having a composition consisting approximately
of twenty-one percent (21%) oxygen, seventy-nine percent (79%) nitrogen and
traces of other gases at one (1) atmosphere of pressure.

         "Confidential Information" means all knowledge and information, whether
written or unwritten, of or pertaining to this Agreement and the transactions
and Project contemplated hereby, the Technology, OxyNet, NetMed or Generon, and
any and all trade secrets, know-how, methodologies, formulae, plans, inventions,
drawings, discoveries, concepts and ideas, whether or not patentable or
copyrightable, of or relating to any of the foregoing; the nature and results of
any research and/or development activities, including products, applications,
methods and services relating to, used or useful in connection with any of the
foregoing or the commercial exploitation thereof; methods, techniques and
strategies used or useful in manufacturing, developing and/or marketing products
or services; non-public information; and existing or prospective customer lists
and requirements, customer data, pricing matters and marketing techniques.

         "Continuation" means, with respect to patents and patent applications,
a refiling of a specification filed in a prior patent application for which
priority is claimed, in whole or in part, with or without the presence of new
matter or of matter or claims divided from the prior patent

                                       2
<PAGE>   3

application, and without regard to whether or not a patent has matured from the
prior patent application.

         "Covered Period" shall have the meaning set forth in Section 4.2.

         "Deoxification Applications" means (a) use of the Technology to remove
oxygen from inert gases where the intended and primary product is the purer
inert gas, including use of the Technology alone or in conjunction with
Generon's membrane or other technology for these purposes; (b) use of the
Technology in connection with Generon's on-site membrane gas generation systems,
including the use of purifying the "oxygen waste air stream"; and (c) so long as
the primary purpose of the use of the Technology is for removing oxygen from a
gas which is being purified, use of the Technology to purify the oxygen waste
stream, provided, however, that Generon may only use the technology in
conjunction with its on-site membrane systems for this purpose.

         "Generon Indemnitees" shall have the meaning set forth in Section 8.1.

         "Generon Restricted Parties" shall have the meaning set forth in
Section 7.1(b).

         "Initial Disclosure Completion Date" shall have the meaning set forth
in Section 2.2. "

         Initial Project Schedule" shall have the meaning set forth in Section
2.2.

         "License Agreement" means the Exclusive License Agreement, in the form
attached hereto as Schedule A, among OxyNet, NetMed and Generon.

         "Licensed Patents" means the patents and patent applications set forth
on Schedule B hereto and the reexamination thereof, and any patents which may
issue from such applications and any Continuations of any of the foregoing, all
patents issued, reissued, reexamined, renewed and/or extended from any of the
foregoing, and all counterparts (that is, corresponding foreign applications and
patents) and equivalents (that is, statutorily protected or designated with the

                                       3
<PAGE>   4

status of an invention, characterized as other than a patent or patent
application) of any of the foregoing filed or issued in any country of the
world, which are or were filed, owned (legally or beneficially, in whole or in
part), licensed or acquired by OxyNet or NetMed at any time prior to or during
the term of this Agreement or of the License Agreement.

         "Liens and Encumbrances" means and includes any and all liens,
mortgages, pledges, assignments, security interests, charges, encumbrances,
claims, options, and other rights or contingent rights of whatever nature which
might impair or affect title (legal or beneficial) to, or ownership or
possession of, property, and whether contractual, statutory, common law,
express, implied or equitable in nature.

         "Losses" shall have the meaning set forth in Section 8.1.

         "Oxy Confidential Information" shall have the meaning set forth in
Section 7.1(b).

         "Oxy Restricted Parties" shall have the meaning set forth in Section
7.1(a).

         "Parties" means OxyNet, NetMed and Generon, collectively.

         "Person" means any individual, corporation, firm, proprietorship,
partnership, association, limited liability company or partnership, joint stock
company, joint venture company, trust, unincorporated association, government or
governmental agency or body or any other group or entity no matter how organized
and whether or not for profit.

         "Project" means a research and development program consisting of
multiple phases, including a prototype development phase ("Phase I"), a
prototype testing phase ("Phase II"), an economic assessment phase ("Phase
III"), and scale-up and commercial exploitation of the Technology for use in or
relating to Deoxification Applications.

         "Project Period Inventions" shall have the meaning set forth in Section
4.2.

                                       4
<PAGE>   5

         "Reimbursement and Security Agreement" means the Reimbursement and
Security Agreement dated the date hereof between OxyNet and Generon, in which
OxyNet has granted to Generon a first lien and security interest in the
CeramPhysics License, as more fully described therein.

         "Related Agreements" means the other agreements and documents executed
and/or delivered pursuant to or in connection with this Agreement, including the
License Agreement, the Reimbursement and Security Agreement, and those other
documents delivered prior to the date hereof regarding the subject matter of
this Agreement.

         "Technology" means OxyNet's and/or NetMed's owned and/or licensed
technology (including the Licensed Patents, patents, patent applications,
reissues and Continuations, know-how, Confidential Information, trade secrets,
manufacturing methods, drawings, laboratory notes and other information however
embodied or expressed (and whether oral, in writing or stored on
machine-readable media such as magnetic tapes, compact discs or other means))
relating to, used or useful in the removal, concentration or separation of
oxygen from air and/or other gases.

         1.2 Words importing singular number shall include the plural number,
and vice versa, and the masculine shall include the feminine, and vice versa.
Unless expressly indicated otherwise, the use of the words "herein," "hereby,"
"hereunder," "hereof," "hereinafter," or other similar words refer to the entire
Agreement, including the Schedules and Exhibits hereto, if any, and not solely
to the particular Section or Subsection in which such word is used, and the word
"including" means "including, but not limited to," and words of similar import,
such as "includes" mean "includes, without limitation."

                                       5
<PAGE>   6

         SECTION 2 DEVELOPMENT PROJECT.
                   -------------------

         2.1 Promptly following execution of this Agreement, and in any event
within fourteen (14) days thereafter, and from time to time thereafter as
requested by Generon, OxyNet and NetMed shall disclose, in writing if requested,
to Generon, its designated employees and agents, any and all information
relevant to the Technology, the Confidential Information, the Project or
implementation of this Agreement.

         2.2 Following completion of the initial disclosure pursuant to Section
2.1 (the "Initial Disclosure Completion Date"), and based upon such disclosure
and the estimates provided by OxyNet and NetMed, Generon shall promptly prepare
a Project schedule setting forth Generon's best estimate of the tasks to be
performed, the dates by which it expects such tasks to be completed and the cost
thereof (the "Initial Project Schedule"). OxyNet and NetMed shall cooperate with
Generon and provide such assistance as Generon shall reasonably request
regarding the preparation of the Initial Project Schedule. From time to time, as
in Generon's view circumstances warrant, Generon shall revise and update the
Initial Project Schedule, a copy of which revised schedule shall promptly be
delivered to OxyNet and NetMed.

         2.3 Generon shall commence work on the Project as soon as reasonably
practicable following completion of the Initial Project Schedule. Thereafter,
subject to the provisions hereof, including Section 6.2, Generon will diligently
pursue completion of Phases I, II and III. Nothing in this Agreement or the
Related Agreements shall require or be construed to require that Generon proceed
with scale-up or commercial exploitation of the Technology or otherwise proceed
beyond Phase III.

         2.4 Anything herein to the contrary notwithstanding, Generon shall
control all aspects of the Project, its progress and implementation.

                                       6
<PAGE>   7

         2.5 Generon shall bear the cost of Phases I, II and III, up to the
amounts set forth in Schedule C hereof.

         SECTION 3 CONSIDERATION.
                   -------------

         3.1 Upon the execution and delivery of this Agreement by all Parties,
Generon shall pay to OxyNet and NetMed the aggregate sum of the TWO HUNDRED
FIFTY THOUSAND DOLLARS ($250,000) in consideration of their performance of their
obligations under this Agreement.

         3.2 In the event Generon proceeds to exploit commercially the
Technology, it shall pay to OxyNet the royalties set forth in the License
Agreement.

         SECTION 4 GRANT OF RIGHTS; OWNERSHIP.
                   ---------------------------

         4.1 OxyNet hereby grants to Generon all rights to the Technology for
use or application in or in connection with Deoxification Applications. The
rights granted in this Section 4.1 are (a) exclusive (including as to OxyNet and
NetMed) and worldwide, (b) are in addition to the rights granted Generon
elsewhere in this Agreement and/or in the License Agreement, and (c) are
irrevocable and, except as otherwise may be provided in the License Agreement
respecting royalties if earned, fully paid-up.

         4.2 The Parties covenant and agree that all patents (other than the
Licensed Patents) and all inventions, ideas, know-how, discoveries,
improvements, reports, writings, programs, algorithms, documentation, works,
Confidential Information and all property rights, including intellectual
property rights, in or respecting the foregoing and the use and practice thereof
and the derivative use thereof, including all patents, copyrights and
trademarks, patent applications, Continuations and copyright and trademark
registrations, and any and all trade secrets, secret processes, products,
hardware, software and firmware (in whatever form or media) made,

                                       7
<PAGE>   8

discovered, invented, created, conceived or acquired by any Party or any
employee, subcontractor or agent of any Party, and whether made jointly or in
collaboration with any other Person, with respect to or in connection with the
Project or any aspect thereof or under or pursuant to this Agreement or related
to the subject matter hereof during the term of this Agreement and for a period
of twelve (12) months thereafter (the "Covered Period") (all of the foregoing
being referred to collectively as the "Project Period Inventions") are, and
shall be, the sole and exclusive property of Generon; provided, however, that
Project Period Inventions shall not include any intellectual property not
related to or useful in respect of Deoxification Applications which is
separately and independently developed by OxyNet or NetMed the costs of
development of which are not funded by Generon. Generon's rights in and to the
Project Period Inventions shall include all rights of reproduction, derivation,
use, practice, distribution and public performance and display by any and all
means, methods and processes now known or hereafter created, invented, conceived
or devised and in all manner, medium or form, now known or hereafter created,
invented, conceived or devised. OXYNET AND NETMED ACKNOWLEDGE AND AGREE THAT
GENERON IS THE SOLE AND EXCLUSIVE OWNER OF THE PROJECT PERIOD INVENTIONS AND ALL
RIGHTS THEREIN.

         4.3 OxyNet and NetMed agree to make full and timely written disclosure
to Generon, and to cause their employees, subcontractors and agents to make full
and timely written disclosure to Generon, of all inventions, ideas, know-how,
discoveries, improvements, reports, programs, algorithms, copyrights, trade
secrets, secret processes, programs and other useful information and
documentation with respect to the Project or this Agreement or any aspect
thereof conceived, made or acquired during the Covered Period and shall
otherwise maintain the foregoing in strict confidence. In all events, such
disclosure shall be made within thirty (30) days

                                       8
<PAGE>   9

after the inventor first discloses the same to OxyNet or NetMed and shall
include such detail as to enable one skilled in the art to use, make or practice
the invention. To the extent known, such disclosure shall include any statutory
bars to patentability. All such written disclosures shall be marked as
confidential and otherwise shall contain such markings as necessary to protect
and preserve patentability of the invention under any relevant law.

         4.4 Generon shall have the exclusive right to apply for and/or register
any and all copyrights, trademarks, patents and other means of protection as
Generon in its sole discretion deems necessary or desirable in respect of all or
any part of the Project Period Inventions. OxyNet and NetMed covenant and agree,
and covenant and agree to use reasonable efforts to cause their employees,
subcontractors and agents, to cooperate and. assist in and in respect of any
such registration or application as requested from time to time by Generon.

         4.5 OxyNet and NetMed covenant and agree, and covenant and agree to use
reasonable efforts to cause their employees, subcontractors and agents, to
execute and deliver such documents and writings (including assignments and
affidavits) and provide such assistance and cooperation as from time to time may
be requested by Generon to obtain, perfect and/or to protect the rights and
interests of Generon herein set forth, including assistance in filing patent,
copyright and trademark applications and/or registrations in the United States
or elsewhere in Generon's name or as designated by Generon.

         4.6 The Parties intend, regarding copyrights, that the Project Period
Inventions be and be deemed "works made for hire" for Generon as such term is
defined by any applicable law.

         4.7 OxyNet and NetMed hereby irrevocably and unconditionally sell,
convey, assign and transfer to Generon (or its designee), without the necessity
of any consideration in addition to that recited herein, and covenant and agree
to cause each of their employees, subcontractors

                                       9
<PAGE>   10

and agents to sell, convey, assign and transfer to Generon all right, title and
interest in and to the Project Period Inventions. The foregoing assignment is a
present assignment and shall, without further act or deed, be operative and
effective with respect to all property rights (including intellectual property
rights) in and to, or in respect of, the Project Period Inventions, including
(i) all copyrights in the United States and elsewhere, including all rights of
registration and publication, rights to perform and/or make copies of the
Project Period Inventions and to create derivative works, and all other rights
incident to copyright ownership, (ii) all trademarks, trade secrets, inventions,
discoveries, patents, patent applications, Continuations, know-how, ideas and
Confidential Information relating to and/or embodied or reflected in the Project
Period Inventions, including any and all shop rights and moral rights for the
longest period of protection accorded to such interests under applicable law.
OxyNet and NetMed and their employees, subcontractors and agents shall retain no
rights whatsoever in or in respect of any Project Period Inventions. OxyNet and
NetMed covenant and agree, and covenant and agree to use reasonable efforts to
cause their employees, subcontractors and agents, not to contest or challenge
Generon's rights, including trademarks, copyrights and patents, in and to or in
respect of any Project Period Inventions. The assignments contemplated hereby
include any and all rights to secure any Continuations, reissues, renewals,
extensions of or other rights relating to trademarks, copyrights and patents in
the United States and/or elsewhere relating to Project Period Inventions. OxyNet
and NetMed agree and confirm (and from time to time as requested by Generon
shall reconfirm) and covenant and agree to use reasonable efforts to cause their
employees, subcontractors and agents to agree, confirm and reconfirm, that the
assignments and transfers provided herein include all right, title and interest
in, to or in respect of the Project Period Inventions, all parts, variations,
enhancements, modifications, improvements, developments, prototypes and

                                       10
<PAGE>   11

documentation thereof, all property rights (including intellectual property
rights) associated therewith, and all causes of action for any infringement of
such rights, and the right to receive, use and retain any proceeds relating to
such infringements.

         4.8 As used herein, "Intentionally Abandon" means a determination by
Generon, in its sole and absolute discretion, to abandon permanently the
Project. "Implied Abandonment" means a failure on the part of Generon lasting
for more than twelve (12) months following completion of Phase III to take
action to proceed with scale-up or commercialization of the Licensed Technology.
Any dispute between the Parties as to whether an Implied Abandonment has
occurred shall be resolved by way of arbitration as provided herein. "Permitted
Partner" means a Person other than a Person engaged in the industrial gas
industry.

             In the event Generon determines to Intentionally Abandon the
Project, it may give written notice of such determination to OxyNet (a
"Discretionary Abandonment Notice"), In the event of an Implied Abandonment
OxyNet may give written notice of such occurrence to Generon at any time prior
to Generon's taking any action to proceed with scale-up or commercialization of
the Licensed Technology (an "Implied Abandonment Notice"). Upon OxyNet's receipt
of a Discretionary Abandonment Notice or Generon's receipt of a proper Implied
Abandonment Notice which is not contested by Generon within sixty (60) days
after receipt of such notice by written notice to OxyNet, OxyNet, at its
request, shall be granted an exclusive sublicense of the Licensed Technology
(except as to Generon's continuing rights in and to the Licensed Technology,
which shall not be diminished in any respect by such grant to OxyNet) for
Deoxification Applications, provided that it shall first enter into an exclusive
sublicense agreement with Generon pursuant to which it shall pay to Generon a
royalty of [*] and otherwise be in form and
substance reasonably determined by

* Portion has been omitted pursuant to a request for confidential treatment and
  filed separately with the Commission

                                       11
<PAGE>   12

Generon (the "Exclusive Oxy Sublicense"). Thereafter, Generon and OxyNet shall
both be free to pursue commercialization of the Licensed Technology.

                  In the event OxyNet enters into the Exclusive Oxy Sublicense,
as aforesaid, it may also receive an exclusive license to the Project Period
Inventions (except as to Generon's continuing rights in and to the Project
Period Inventions, which shall not be diminished in any respect by such grant to
OxyNet) for Deoxification Applications upon the payment to Generon, at the time
of entering into of the Exclusive Oxy Sublicense, of [*] plus such additional
sum as shall be mutually agreed to by OxyNet and Generon on account of Generon's
costs and expenses paid or incurred in connection with the Project. Such license
shall also bear royalties at the rate of [*].

         4.9 At OxyNet's written request, subject to the execution and delivery
of a mutually satisfactory license agreement as provided below, it shall be
granted a non-exclusive, personal, non-transferable and non-assignable (by
agreement, operation of law or otherwise) license of the Project Period
Inventions for use by OxyNet in connection with the use by it of the Technology
in generating oxygen from Ambient Air. In no event shall OxyNet use or be
permitted to use or practice Project Period Inventions in competition with
Generon or its Affiliates. Such license shall be effective only upon execution
and delivery, shall provide for such royalties, shall prohibit sublicensing,
assignment or other transfer by OxyNet and shall contain such other terms and
conditions as the parties may, each in the exercise of their individual
discretion, agree.

         4.10 The provisions of Section 4 shall survive any termination or
expiration of this Agreement for any reason.

* Portion has been omitted pursuant to a request for confidential treatment and
  filed separately with the Commission

                                       12
<PAGE>   13

         SECTION 5 REPRESENTATIONS AND WARRANTIES.
                   -------------------------------

         5.1 OxyNet and NetMed, jointly and severally, represent and warrant to
Generon that:

             5.1.1 Each of OxyNet and NetMed is a corporation duly organized,
validly existing and in good standing under the laws of the State of Ohio.

             5.1.2 Each of OxyNet and NetMed has all requisite power and
authority to enter into this Agreement and each Related Agreement to which it is
a party, and to perform its obligations hereunder and under any such Related
Agreements. The execution, delivery and performance of this Agreement and the
Related Agreements by OxyNet and/or NetMed have been duly and validly authorized
by all necessary corporate action. This Agreement and each of the Related
Agreements constitutes a legal, valid and binding obligation of OxyNet and/or
NetMed (as appropriate) enforceable against them in accordance with its terms
(except as enforcement may be limited by bankruptcy, insolvency or similar laws
of general application).

             5.1.3 Neither the execution and delivery of this Agreement or any
Related Agreement nor the consummation of the transactions contemplated hereby
or thereby (a) will conflict with or result in a breach, default or violation of
(i) the articles of incorporation or regulations of OxyNet or NetMed, or (ii)
any permit, contract or agreement to which OxyNet and/or NetMed is a party or is
subject or by which either or both of them is or are bound. No consent, action,
approval or authorization of, or registration, declaration or filing with, any
Person is required to authorize, or in connection with the execution, delivery
and/or performance of, this Agreement or any Related Agreement by OxyNet and/or
NetMed.

             5.1.4 OxyNet owns (of record and beneficially) and/or has licensed
exclusively (as exclusive licensee) the Licensed Patents and Technology free and
clear of any Liens and Encumbrances.

                                       13
<PAGE>   14

             5.1.5 The Licensed Patents and Technology do not, and the
commercial exploitation thereof by Generon will not to the best knowledge of
OxyNet and NetMed, conflict with, infringe or otherwise violate any rights or
property of any Person.

             5.1.6 Except as disclosed on Schedule D hereto, there is no
litigation or proceeding presently pending or threatened, nor to OxyNet's and
NetMed's knowledge is there any basis for any litigation or proceeding,
respecting (i) the ownership, validity or use of the Licensed Patents or
Technology, or (ii) which might adversely affect the ownership, validity or use
of the Licensed Patents or Technology.

             5.1.7 None of the representations or warranties contained herein
and, to the best knowledge of OxyNet and NetMed, none of the information
delivered in connection herewith or heretofore provided by OxyNet or NetMed to
Generon, contains any untrue statement of fact or omits any information or fact
necessary to make the statements made herein or therein not misleading.

         5.2 Generon represents and warrants to OxyNet and NetMed that:

             5.2.1 Generon is a corporation duly organized, validly existing and
in good standing under the laws of Delaware.

             5.2.2 Generon has all requisite power and authority to enter into
this Agreement and each Related Agreement to which it is a party, and to perform
its obligations hereunder and under any such Related Agreement. The execution,
delivery and performance of this Agreement and the Related Agreements by Generon
have been duly and validly authorized by all necessary corporate action. This
Agreement and each of the Related Agreements constitutes a legal, valid and
binding obligation of Generon enforceable against it in accordance with its
terms (except as enforcement may be limited by bankruptcy, insolvency or similar
laws of general application).

                                       14
<PAGE>   15
                  5.2.3 Neither the execution and delivery of this Agreement or
any Related Agreement nor the consummation of the transactions contemplated
hereby or thereby (a) will conflict with or result in a breach, default or
violation of (i) the certificate of incorporation or bylaws of Generon, or (ii)
any permit, contract or agreement to which Generon is a party or is subject or
by which it is bound. No consent, action, approval or authorization of, or
registration, declaration or filing with, any Person is required to authorize,
or in connection with the execution, delivery and/or performance of, this
Agreement or any Related Agreement by Generon.

                  5.2.4 None of the representations or warranties contained
herein and, to the best knowledge of Generon, none of the information delivered
in connection herewith or heretofore provided by Generon to OxyNet or NetMed,
contains any untrue statement of fact or omits any information or fact necessary
to make the statements made herein or therein not misleading.

         SECTION 6 CERTAIN COVENANTS.
                   -----------------

         6.1 Contemporaneous with the execution and delivery of this Agreement,
the Parties shall execute and deliver, or cause to be executed and delivered,
the License Agreement, and the other Related Agreements contemplated so to be
executed and delivered at such time.

         6.2 OxyNet and NetMed covenant and agree to cooperate fully with
Generon as from time to time reasonably requested by Generon including the
assignment of all personnel and employees of OxyNet and/or NetMed as shall in
Generon's reasonable discretion be necessary or useful to enable Generon to
timely complete and effectuate the Project, including Phases I, II and III
thereof. Without limiting the generality of the foregoing, OxyNet and NetMed
shall use their best efforts to make available to Generon the time and services
of [*] as in Generon's reasonable discretion shall be necessary or useful to
enable

* Portion has been omitted pursuant to a request for confidential treatment and
  filed separately with the Commission

                                       15
<PAGE>   16
Generon to timely complete and effectuate the Project, including Phases I, II
and III thereof. In addition, OxyNet and NetMed shall use reasonable efforts to
cause [*] to enter into a consulting agreement with Generon, on the date hereof,
in form and substance acceptable to Generon, to be effective in the event of [*]
termination of employment with NetMed, provided, however, that Generon's
obligations hereunder, including payment of the consideration described in
Section 3.1, shall be subject to and conditioned upon [*] execution and delivery
of such consulting agreement. In the event that [*] is not available to Generon
as it deems necessary or desirable, OxyNet and NetMed shall procure for Generon
the services of another Person, as shall be acceptable to Generon in its sole
discretion, having at least the level of skill an knowledge as [*].

         SECTION 7 CONFIDENTIALITY.
                   ---------------

         7.1 (a) OxyNet and NetMed acknowledge and agree that before and during
the term of this Agreement they and their Affiliates, employees, subcontractors
and agents (collectively and individually, the "Oxy Restricted Parties") have
been and will continue to be exposed to Confidential Information. During the
term of this Agreement and indefinitely thereafter the Oxy Restricted Parties,
either individually or with or on behalf of any other Person, covenant and agree
that they shall not, directly or indirectly, disclose, disseminate, publish,
reproduce, use or otherwise make available in any manner or media whatsoever any
Confidential Information to or for any Person without the prior written consent
of Generon, nor shall any Oxy Restricted Party use or retain any Confidential
Information for their own account, gain or benefit. OxyNet and NetMed further
covenant and agree, for themselves and for the other Oxy Restricted Parties,
that all copies of all papers, books, records, documents and other property of
whatever kind now or hereinafter in their possession, custody or control which
reflects or contains or is

* Portion has been omitted pursuant to a request for confidential treatment and
  filed separately with the Commission

                                       16
<PAGE>   17

derived from any Confidential Information shall be delivered to Generon as from
time to time requested by Generon. OxyNet and NetMed shall cause each of their
employees, subcontractors and agents who have or have access to any Confidential
Information to execute and deliver to Generon a covenant to and for Generon's
benefit confirming the provisions hereof. The foregoing confidentiality covenant
shall not apply to Confidential Information which (i) becomes generally
available to the public other than as a result of disclosure by a Oxy Restricted
Party, (ii) was available to the Oxy Restricted Parties on a non-confidential
basis prior to the date of this Agreement as reflected by written evidence of
such state of affairs existing in such Oxy Restricted Party's files prior
hereto, or (iii) becomes generally available on a non-confidential basis from a
source other than an Oxy Restricted Party or Generon, provided such source is
not obligated to keep such information confidential.

             (b) Generon acknowledges and agrees that before and during the term
of this Agreement, it and its Affiliates, employees, subcontractors and agents
(collectively and individually, the "Generon Restricted Parties") have been and
will continue to be exposed to confidential information owned solely by OxyNet
or NetMed and not constituting a part of the Technology or Project Period
Inventions ("Oxy Confidential Information"). Generon's rights respecting the
Technology and Project Period Inventions are and shall continue to be
unrestricted by this Subsection (b). During the term of this Agreement and
indefinitely thereafter the Generon Restricted Parties, either individually or
with or on behalf of any other Person, covenant and agree that they shall not,
directly or indirectly, disclose, disseminate, publish, reproduce, use or
otherwise make available in any manner or media whatsoever any Oxy Confidential
Information to or for any Person without the prior written consent of OxyNet or
NetMed. Generon further covenants and agrees, for itself and for the other
Generon Restricted Parties, that all copies of all

                                       17
<PAGE>   18

papers, books, records, documents and other property of whatever kind now or
hereinafter in their possession, custody or control which reflects or contains
or is derived from any Oxy Confidential Information shall be delivered to OxyNet
and NetMed as from time to time requested by OxyNet and NetMed. Generon shall
cause each of its employees, subcontractors and agents who have or have access
to any Oxy Confidential Information to execute and deliver to OxyNet and NetMed
a covenant to and for OxyNet and NetMed's benefit confirming the provisions
hereof. The foregoing confidentiality covenant shall not apply to Oxy
Confidential Information which (i) becomes generally available to the public
other than as a result of disclosure by a Generon Restricted Party, (ii) was
available to the Generon Restricted Parties on a non-confidential basis prior to
the date of this Agreement as reflected by written evidence of such state of
affairs existing in such Generon Restricted Party's files prior hereto, or (iii)
becomes generally available on a non-confidential basis from a source other than
a Generon, Restricted Party or OxyNet and NetMed, provided such source is not
obligated to keep such information confidential.

         7.2 In the event that any Oxy Restricted Party or Generon Restricted
Party becomes legally compelled, or is served with any legal process which may
compel them, to disclose any Confidential Information or Oxy Confidential
Information, respectively, OxyNet and NetMed or Generon, as appropriate, shall
provide the other party with prompt prior written notice so as to enable OxyNet
or Generon, as appropriate to seek to protect, by protective order or otherwise,
the confidentiality of such information.

         7.3 The provisions of this Section 7 shall survive any termination or
expiration of this Agreement for any reason. The parties acknowledge and agree
that any breach or threatened breach of any of the provisions of this Section 7
will result in immediate and irreparable harm to

                                       18
<PAGE>   19

the non-breaching party and that any remedy at law in such event will be
inadequate. Accordingly, the non-breaching party shall be entitled to injunctive
relief in respect of any such breach or threatened breach without the need to
post a bond or provide other security, which are hereby waived. The foregoing
remedies shall be in addition to and not in lieu of any other remedies which may
be available at law or in equity on account of any such breach or threatened
breach.

         SECTION 8 INDEMNIFICATIONS: NON-ELECTION OF REMEDY.
                   ----------------------------------------

         8.1 (a) OxyNet and NetMed, jointly and severally, covenant and agree
to, and hereby do, indemnify, defend and hold harmless Generon and its
Affiliates, employees, shareholders, officers, directors, and agents (the
"Generon Indemnitees") from and against any and all suits, actions, demands,
damages, losses, claims, liabilities, costs and expenses (including attorneys'
fees and expenses) (collectively, "Losses") arising out of, resulting from in
whole or in part or related to any one or more of the following:

                 (i) breach of any of OxyNet or NetMed's representations or
warranties in this Agreement or any Related Agreement; or

                 (ii) breach of any covenant or agreement contained in this
Agreement or any Related Agreement by OxyNet, NetMed or any Restricted Party; or

                 (iii) any infringement by the Technology or the use or
practice thereof of any intellectual property or contract rights of any other
Person.

             (b) Generon covenants and agrees to, and hereby does, indemnify,
defend and hold harmless OxyNet and NetMed and their Affiliates, employees,
shareholders, officers, directors, and agents from and against any and all
Losses arising out of, resulting from in whole or in part or related to any one
or more of the following:

                                       19
<PAGE>   20

                 (i) breach of any of Generon's representations or warranties in
this Agreement or any Related Agreement; or

                 (ii) breach of any covenant or agreement contained in this
Agreement or any Related Agreement by Generon or any Generon Restricted Party.

         8.2 In addition to and not in limitation of any other rights Generon
may have in such event, in the event that Generon is prohibited from using,
practicing or employing the Licensed Patents and/or Technology, in whole or in
material part as a result of any breach by NetMed or OxyNet of any of their
respective obligations herein, or as a result of any infringement by the
Technology or the use or practice thereof of any intellectual property or
contract rights of any Person, then OxyNet and NetMed, jointly and severally,
covenant and agree forthwith to pay to Generon the sum of (i) $250,000 plus
interest at the rate of seven and one-half percent (7.5%) compounded annually
from the date hereof through the date of payment hereunder to Generon, and (ii)
all costs, payments and expenditures made or incurred by Generon pursuant to
this Agreement through the date of such event plus interest thereon at the rate
of seven and one-half percent (7.5%) compounded annually from the date such
cost, payment or expenditure was made or incurred through the date of payment
hereunder to Generon.

         8.3 OxyNet and NetMed acknowledge and agree that their compliance and
compliance by their employees, subcontractors and agents with the terms of this
Agreement is necessary to protect the goodwill and business of Generon and the
property rights of Generon in and to the Project Period Inventions and
Confidential Information and that any breach or violation (or threatened breach
or violation) hereof will cause continuing, immediate and irreparable injury to
Generon for which money damages would not be an adequate remedy. Accordingly,
OxyNet and NetMed further agree that Generon shall have the right to enforce the

                                       20
<PAGE>   21

provisions of this Agreement and the Related Agreements by injunctive (both
affirmative and negative) or other equitable relief and waive any right to
assert any claim or defense that Generon has an adequate remedy at law for any
such breach or violation. In such regard, it shall not be required or necessary
that Generon post any bond or provide any security as a condition to such
relief.

         8.4 Nothing in this Agreement or otherwise shall constitute an election
of remedies by Generon or otherwise in any way limit Generon's remedies at law
or in equity in respect of any breach or violation hereof by OxyNet, NetMed or
any other Restricted Party. No remedy conferred herein is intended to be
exclusive of any other remedy and each and every remedy shall be cumulative and
in addition to every other remedy now or hereafter available.

         8.5 (a) All claims and controversies, whether based in contract, tort
or otherwise, arising out of or relating to this Agreement or any of the Related
Agreements, or the scope, breach, termination or validity of this Agreement or
any of the Related Agreements, and including any claim or dispute concerning a
party's right to indemnification and any dispute as to the existence of an
Implied Abandonment (a "Claim"), shall be submitted to binding arbitration in
accordance with the following provisions. Arbitration shall be the sole and
exclusive remedy of the Parties in connection with any Claims hereunder.

             (b) The Party desiring to initiate arbitration in connection with
any Claim shall send, via certified mail, written notice of demand of
arbitration to the other Party and the name of the arbitrator appointed by the
Party demanding arbitration together with a statement of the matter in
controversy.

             (c) Within fifteen ( 15) days after receipt of such demand, the
receiving Party shall name its arbitrator. If the receiving Party fails or
refuses to name its arbitrator within such

                                       21
<PAGE>   22

15-day period, the second arbitrator shall be appointed, upon request of the
Party demanding arbitration, by a court of competent jurisdiction in the
Commonwealth of Pennsylvania or such other Person designated by such Court. The
two arbitrators so selected shall within fifteen (15) days after their
designation select a third arbitrator; provided, however, that if the two
arbitrators are not able to agree on a third arbitrator within such fifteen (15)
day period, either Party may request a court of competent jurisdiction in the
Commonwealth of Pennsylvania or such other Person designated by such Court to
select the third arbitrator as soon as possible. In the event the Court declines
to appoint an arbitrator, appointment shall be made, upon application of either
Party, pursuant to the Commercial Arbitration Rules of the American Arbitration
Association. If any arbitrator refuses or fails to fulfill his or her duties
hereunder, such arbitrator shall be replaced by the Party which selected such
arbitrator (or if such arbitrator was selected by another Person, through the
procedure which such arbitrator was selected) pursuant to the foregoing
provisions.

             (d) The arbitrators selected by the Parties are not required to be
neutral, but the third arbitrator shall be neutral and shall be a retired judge
who has served either as a trial court judge in a state or federal district
court, or as a state or federal appellate court judge.

             (e) The Parties hereto hereby request and consent to the three (3)
arbitrators conducting a hearing in Pittsburgh, Pennsylvania no later than sixty
(60) days following their selection or thirty (30) days after all prehearing
discovery has been completed, whichever is later, at which the Parties shall
present such evidence and witnesses as they may choose, with or without counsel.

                                       22
<PAGE>   23

             (f) Except as modified by this Agreement, arbitration shall be
conducted in accordance with the Commercial Arbitration Rules and procedures of
the American Arbitration Association.

             (g) Adherence by the arbitrators to formal rules of evidence shall
not be required. The arbitrators shall consider any evidence and testimony that
they determine to be relevant.

             (h) The Parties hereto hereby request that the arbitrators render
their decision within thirty (30) calendar days following conclusion of the
hearing.

             (g) Any decision by a majority of the arbitration panel shall be
final, binding and non-appealable. Any such decision maybe filed in any court of
competent jurisdiction and may be enforced by any Party as a final judgment in
such court.

             (j) The statute of limitations and any equitable period of laches
shall be tolled from and after the date a Party gives the other Party written
notice of a Claim as provided in Section 8.5 above until such time as the Claim
has been resolved pursuant to Section 8.5, or an arbitration decision has been
entered pursuant to Section 8.5.

             (k) Either Party may apply to the arbitrators seeking injunctive
relief until the arbitration award is rendered or the controversy is otherwise
resolved. Either Party also may, without waiving any remedy under this
Agreement, seek from any court having jurisdiction any interim or provisional
relief that is necessary to protect the rights or property of the Party, pending
the establishment of the arbitral tribunal or pending the arbitral tribunal's
determination of the merits of the controversy.

                                       23
<PAGE>   24

         SECTION 9 FURTHER ASSURANCES.
                   ------------------

         9.1 OxyNet and NetMed covenant and agree that they shall from time to
time, and shall cause their employees, subcontractors and agents to, without
further consideration execute, acknowledge and deliver any and all further
assignments, affidavits, conveyance documents and other assurances, documents
and instruments as may be reasonably requested by Generon and shall take any
other action that may be reasonably requested by Generon for the purpose of
effectuating this Agreement or any Related Agreement or any transaction
contemplated hereby or thereby or to assist or enable Generon to perform its
responsibilities or obligations under this Agreement or any Related Agreement or
to grant, transfer, effect or confirm any right granted or intended to be
granted to Generon pursuant to or in respect of this Agreement or any Related
Agreement.

         SECTION 10 OPTION TO PURCHASE: OTHER APPLICATIONS.
                    ---------------------------------------

         10.1 [*]

* Portion has been omitted pursuant to a request for confidential treatment and
  filed separately with the Commission

                                       24
<PAGE>   25
         SECTION 11 NOTICE.
                    ------

         11.1 Any notice, request, demand or other communication required or
permitted to be given by one Party to any other Party pursuant to this Agreement
shall be sufficiently given and shall be deemed given when delivered personally
or by courier service or mailed by registered or certified mail, postage
prepaid, or sent by telecopy (with receipt confirmed), addressed as follows:

         If to Generon, to:

                  MG Generon, Inc.
                  5 Great Valley Parkway
                  Malvern, Pennsylvania 19033-0739
                  Attention: President
                  Fax:  (610) 695-7766

         If to OxyNet or NetMed:

                  NetMed
                  6189 Memorial Drive
                  Dublin, Ohio 43017
                  Attention: President
                  Fax:  (614) 793-9376

         A Party may, by written notice to the other Parties, designate any
further or different addresses as to which any such communications shall be
sent.

         SECTION 12 MISCELLANEOUS.
                    -------------

         12.1 If any section of this Agreement is adjudicated to be invalid or
unenforceable in whole or in part, the Parties agree that any court of
appropriate jurisdiction may modify or

                                       25
<PAGE>   26

reform such provision or application to make it enforceable in such jurisdiction
and that any other provision or application of this Agreement shall nevertheless
be valid and binding.

         12.2 In connection with the enforcement of any arbitration decision as
provided in Section 8.5, each Party hereby irrevocably submits to the
jurisdiction of the courts of the Commonwealth of Pennsylvania. Each Party
hereby irrevocably waives, to the fullest extent permitted by applicable law,
any objection it may now or hereafter have to the laying of venue of any such
court or any defense of inconvenient forum for the maintenance of such action.
Each Party agrees that service of any process, summons, notice or document by
U.S. registered or certified mail to the addresses set forth in Section 11
hereof (or to any other addresses indicated by such Party to the other Parties
in accordance with the terms of that section) will be effective service of
process for any action, suit or proceeding brought against such Party in
enforcing any rights hereunder. The Parties agree that the rights and
obligations of the Parties hereunder shall be governed by the laws of the
Commonwealth of Pennsylvania, without regard to choice-of-law provisions.

         12.3 Any waiver by any Party of any breach or violation of any term or
condition in this Agreement shall not operate as a waiver of any other breach of
such term or condition or of any other term or condition, nor shall any failure
to enforce any provision hereof operate as a waiver of such provision or of any
other provision hereof or constitute or be deemed a waiver or release of any
other rights, either at law or in equity.

         12.4 This Agreement shall be binding upon, and shall inure to the
benefit of, the Parties hereto and their respective successors and assigns (to
the extent the assignment is permitted hereunder).

                                       26
<PAGE>   27

         12.5 This Agreement (and the Schedules hereto) together with the
Related Agreements set forth all the promises, covenants, agreements, conditions
and understandings among the Parties hereto, and supersede all prior agreements
and understandings, inducements or conditions, express or implied, oral or
written except as contained herein. This Agreement, the Schedules hereto and the
Related Agreements may not be amended or modified other than by an agreement in
writing, executed by the Parties hereto,

         12.6 The Parties agree that the headings of the sections herein are for
the convenience of the Parties only and shall not constitute a part of this
Agreement or affect its meaning or interpretation.

         IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
day and year first written above.

                                  MG Generon, Inc.

                                  By.  /s/ Barry J. Smith
                                     -------------------------------------------
                                  Name: Barry J. Smith
                                  Title: VP and General Manager

                                  OxyNet, Inc.

                                  By.  /s/ David J. Richards
                                     -------------------------------------------
                                  Name: David J. Richards
                                  Title: President

                                  NetMed, Inc.

                                  By.  /s/ David J. Richards
                                     -------------------------------------------
                                  Name: David J. Richards
                                  Title: President

                                       27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}]]